The impact of a reduced calorie, macronutrient diet change on Caucasian males in relation to genotypes associated with obesity, increased BMI and dietary response.

By. Ellis, L and Collins, C.

Muhdo Health Ltd.

Keywords: *genetics, nutrition, obesity, diet, macronutrients.*

Abstract

Obesity is a growing crisis within the 1st world and the causes of obesity are well studied: a lack of physical activity combined with an increased calorie intake. This energy imbalance leads to fat accumulation leading to eventual obesity. Whilst the cause may appear clear, the options of lifestyle change and/or diet planning that is efficient with effective sustainability has been harder to come by. Genetic variants linked to obesity may hold clues on how to best customise a diet plan to an individual leading to an easier to change lifestyle with better sustainability. This study aimed to find correlations with a diet change that decreased kcal intake by 200kcal per day with a macronutrient alteration (decreased carbohydrates and increased unsaturated fat) and genetic components to discover responders and non-responders. Within the study group of Caucasian males the genes TCF7L2, TFAP2B, PPARG2 and FTO all impacted the response of the dietary intervention. In conclusion it would be prudent to consider DNA analysis as part of a battery of diet and lifestyle tests to personalise a sustainable and effective lifestyle/dietary intervention to help control weight.

Introduction

Common knowledge of obesity is a result of when energy intake chronically exceeds energy expenditure, creating a positive net energy balance. And even though the prevention and treatment of obesity is becoming a better studied topic obesity is still increasing worldwide. The fact is, the pathophysiology of the condition is complex and the causes of energy intake and energy expenditure are multifactorial. The main methods of energy expenditure are:

1. BMR
2. Thermic effect of food (TEF)
3. Physical activity
4. Non-exercise activity thermogenesis (NEAT)
5. Newly found genetic predispositions which can increase or decrease natural energy expenditure.

Data has shown that there is a genetic contribution to obesity within populations. Individuals are more likely to develop the phenotypic expression of obesity based upon a permissive role of the environment with the main link being a strong genetic predisposition. Over 40 sites in the human genome have been discovered that can increase genetic susceptibility to obesity including polygenic cases of obesity; multiple gene mutations, single nucleotide polymorphisms and Mendelian obesity⁽¹⁾.

Due to this, nutritional genomics suggests that individuals in the same obesogenic behaviour (environmental interactions), those with genetic mutations that promote obesity will likely gain weight, whereas those without the mutations won't gain weight. Obesity should not be treated as a phenotypic disease; instead effective treatment should incorporate the combination of environmental, physiological, psychological, biochemical and genetic factors ⁽²⁾.

A report outlined that 127 genes with one positive association to obesity had been found and among these, 22 were supported by five positive studies ⁽³⁾. These genes were: ACE, ADIPOQ, ADRB2, ADRB3, DRD2, GNB3, HTR2C, IL6, INS, LDLR, LEP, LEPR, LIPE, MC4R, NR3C1, PPARG, RETN, TNFA, UCP1, UCP2, UCP3 and VDR.

Studies suggest there are five overall genotypes, to which numerous genes can be classified into. These genotypes are:

1. The thrifty genotype – in this genotype, the individual has a low metabolic rate and therefore lower levels of thermogenesis.
2. The hyperphagic genotype – these individuals have poor control over appetite and low satiety levels which means they have an increased risk of overeating
3. The sedentary genotype – this genotype is linked to those with low levels of physical activity (above normal NEAT)
4. The lipid oxidation genotype – these individuals have low levels of lipid oxidation, therefore they do not use fat stores as an energy source in an efficient manner.
5. The adipogenesis genotype – these genotypes are associated with a higher lipid storage capacity which means that overfeeding is likely to expand the adipocyte storage.

There is a synergistic relationship between environmental factors and genes which means that when genetic mutations are present, the risk of obesity is increased and the severity of which is determined through interactions with the environment.

Methods

The aim of this study was to: To investigate the association between genotype and BMI in Caucasian males (n=92) aged between 29 and 38.

Using genetic screening as a tool to improve obesity treatment is becoming more prevalent. The aim of this study was to assess the association between genotypes, BMI and weight. Further to this, macronutrient alteration was used by changing KCAL from carbohydrate to KCAL from fats along with a simple reduction of 200kcal per day over a period of 24 weeks. BMI and weight were assessed in active healthy males (n=92) to determine association of genotypes using a quasi-experimental study design. 78 genes were initially assessed during the 24 week programme that altered only dietary factors of the individuals' lifestyle, no exercise or physical activity protocol were introduced:

- Alteration to macronutrients, 350kcal (87.5 - 90g) was cut from predominately sugar based foods and replaced with 150kcal (16.6 - 20g) of predominately unsaturated fat based foods, leaving a calorie deficit of only 200kcal per day.

Sugar predominant	Swaps (only till 90g sugar MAX)
400ml Orange Juice Pure (168kcal – 32g sugar)	Water

330ml Cola based drink (139kcal – 35g sugar) Other sugar based juices/fizzy drinks with similar 30-40g sugar, 100 -200kcal)	
Common Choc Bar (51g) 229kcal – 30.4g sugar Common Choc Bar #2 (45g) 240kcal – 25g sugar Common Choc Bar #3 (58g) 264kcal – 35g sugar	30-50g of almonds – 167kcal – 13g Unsat fats - 2g sugar
Milkshakes (“health shakes”) Multiple varieties – 300-400kcal, 30-40g sugar, very low in fat. Some high in protein.	1 average avocado – 266kcal – 25g unsat fats – 1g sugar.

Table 1. Example of food swaps

Outliers

Values for total weight loss and BMI loss were checked for unrealistic values and outliers and such values and outliers were excluded from the assessment. Values of weight loss ≥ 15 kg were excluded as they were deemed too excessive following the 24 week intervention.

Stats test

Of the 78 genes which were assessed, only 8 drew attention after removing outliers and removing any missing genotypes. A Hardy-Weinberg test was conducted on all 8 genotypes to show equilibrium. T-tests were conducted for baseline BMI before and after the 24 week intervention. Significant genes from the T-tests underwent a linear regression model to analyse the effects of genotypes on BMI and weight.

Results

5 participants were excluded from the study due to weight loss equal to or above 15kg which was deemed excessive for 24 weeks.

Participants had a mean baseline BMI of 27.9 kg/m^2 and mean weight was 90kg at the start of the study, Following the macronutrient alteration to the diet with a decrease in carbohydrate intake and increase in fat intake on average participants lost -8kg and their BMI decreased by 3.5 kg/m^2 (Table2).

	Pre Intervention	Post Intervention
KCAL Intake	2549	2349
Height (cm)	180	180
BMI	27.9	24.4
Weight (kg)	90	82

Table 2: Descriptive statistics of average pre and post intervention.

8 genes and their respective polymorphism were put into the Hardy Weinberg equilibrium (Table 3) and further analysis was conducted on these genes. T-tests on these 8 genes isolated the results further, and found only 4 genes to be statistically significant pre and post intervention on BMI and

weight loss outcomes. A regression analysis then looked into the effects of the genotypes on the 4 genes which were shown to have significant differences. These were:

TCF7L2 – Average weight loss in C allele (n=24) was -8 KG and BMI loss was -2.6 In the CT (n=5) was -6kg and -1.9. For homozygote T (n=9), no significant difference were found pre and post intervention for weight along (T(34) = 1.09, P < 0.05). No other significant effects were found. Significant differences between pre and post for C allele (T(64) = 6.7, P < 0.05) and between CT allele (t (5) = 7.79, p < 0.05) but no significant differences between groups (T(36) = 2.71, P > 0.005).

Graph 1: TCF7L2 gene variants, weight and BMI change pre and post intervention.

TFAP2B –Average weight loss for A allele (n=21) was -7KG and BMI loss was -2.27 with significant difference (T (40) = 4.86, P< 0.05). Only one participant was homozygous for G allele so data was excluded. For GA allele (n=16) average weight loss was -9kg and BMI loss was -2.87 with significant difference (T (30) = 4.74, P< 0.05). A significant difference was also found between groups for A allele and GA allele, suggesting the A allele was important in controlling weight loss (T (35) = 4.66, P < 0.05).

Graph 2: TFAP2B gene variants, weight and BMI change per and post intervention.

PPARG2 – average weight loss for C (n=31) allele was -8kg and for BMI was -2.41 with significant difference before and after intervention ($T(60) = 6.12$, $p < 0.05$). Only one participant was homozygous for G allele so data was excluded. For GC individuals (n = 6), average weight loss was -10kg and BMI loss was -3.23 which was the highest BMI loss out of all 8 genotypes identified to be significant. Significant differences was found pre ad post intervention for BMI for GC alleles ($T(10) = 3.23$, $p < 0.05$) and similarly pre and post between C homozygous and GC heterozygotes ($T(35) = 4.77$, $P < 0.05$).

Graph 3: PPARG2 gene variants, weight and BMI change pre and post intervention.

FTO – average weight loss for T (n=12) was -10kg with a BMI loss of -3.04, values were significantly different pre and post intervention ($t(22) = 4.61$, $P < 0.05$). A allele (n=4) average weight loss was -9kg and BMI loss of -2.65 and values were significantly different ($t(6) = 2.49$, $p = 0.02$). TA individuals (n=22), BMI loss was -2.3 and weight loss was -7kg and significant differences ($t(42) = 4.76$, $p < 0.05$). Between groups, there was no significant difference between T homozygous and A homozygous ($t(14) = 7.79$, $P > 0.05$) or for T homozygous and TA heterozygous ($t(32) = 3.59$, $P > 0.05$). However a significant effect was found between A homozygous and TA heterozygous for BMI values ($t(24) = 3.04$, $p = 0.002$).

Graph 4: FTO gene variants, weight and BMI change pre and post intervention.

Gene	SNP	Risk Allele	Genotype			Hardy Weinberg	
			NC	HEZ	HOZ	R ²	P
TCF7L2	rs7903146	T	24	5	9	1.35	0.28
TFAP2B	rs987237	G	21	16	1	0.18	0.66
PPARG2	rs1801282	G	31	6	1	1.27	0.25
FTO	rs9939609	A	12	22	4	0.85	0.35

Table 3 – Showing the four genes which were in Hardy-Weinberg equilibrium and had significant effects pre and post intervention. (*NC/HEZ/HOZ = Non carriers / heterozygotes / homozygotes)

Discussion

The field of obesity research is expanding to find a more complex aetiology surrounding the disease. New research suggest that adipose tissues now serves as an endocrine system, and secretes adipocytokines including adiponectin, IL-6, TNF- α and leptin. These cytokines are involved in systemic insulin responses and play a role in increasing symptoms of obesity and potentially leading to type-2 diabetes⁽⁴⁾.

TFAP2B – rs987237

The activating enhancer binding protein (AP)-2b transcription factor gene (**TFAP2B**) has been identified as a susceptible gene to increasing BMI and weight gain through its regulation of adipokine gene expression.

A previous study outlined the effect of the TFAP2B polymorphisms and found that the specific polymorphisms rs987237 had an overexpression of TNF- α in adipose cells ⁽⁵⁾. TNF- α produced in adipose cells has been implicated in systemic insulin resistance which in turn has been one of the major contributors to the pathogenesis of obesity ⁽⁶⁾. The expression of the risk allele “A” has been associated with decreased adiponectin levels in subcutaneous tissue.

Individuals with one or two of the G alleles have been shown to have significantly less leptin ⁽⁸⁾. Leptin is a hormone predominantly made by adipose cells that regulates energy balance by inhibiting hunger levels in the body. A lower level of circulating leptin doesn’t inhibit hunger effectively; the individual doesn’t feel satiated from eating. This could potentially explain why carriers of the risk allele are known to have increased weight compared to their counterparts. Decreasing leptin concentrations are responsible for the starvation-induced suppression of the hypothalamic-pituitary-gonadal axis and can lead to insulin resistance, altering the metabolism of carbohydrate intake ⁽⁹⁾.

FTO – rs993609.

The rs993609 variant of the FTO gene is one of the most common genotypes that has known influence to the response of weight reduction therapy. The A allele of this gene has been shown to be the risk allele that is associated with lower insulin sensitivity and increased BMI levels ⁽¹⁰⁾. A previous study identified the FTO rs993609 can interact with the macronutrient composition in individuals. The risk allele carriers (A allele) responded better to a high fat and low carbohydrate diet, but had higher drop-out rates from the study. High drop-out rates could be explained by a study in 3000+ individuals showing that the AA genotypes had a greater appetite compared to other genotypes, which suggests that this risk allele is likely to influence appetite and reduce satiation ⁽¹¹⁾. The Homozygote T allele individuals had smaller decreases in resting energy expenditure (REE) and insulin release on the low fat higher carbohydrate diet ⁽¹²⁾.

In the present study, A allele individuals (both homozygous and heterozygous) started with the highest weight of all the participants, which could be explained by increased appetite levels and less satiation from their food intake. These individuals should preferentially modify caloric intake through more fat in place of carbohydrates. However this equates to a lower amount of total food consumed which could be difficult to adhere to long term due to the small satiating effects of the risk allele. A recent study also outlined potential differences in response to protein intake with the FTO rs993609 and although protein intake was not changed during this study, normal day to day differences in intake could have affected an individual’s response ⁽¹³⁾.

PPARG2 rs1801282

The peroxisome proliferator-activated receptor gamma 2 (PPARG2) gene is an extensively studied gene in relation to obesity. PPARG has been shown to play a crucial role in adipose tissue formation as well as controlling insulin. It is the insulin response by transcriptional stimulation of adipocyte-

genes which affects lipid storage, glucose and fatty acid uptake that is associated with metabolic disorders such as obesity⁽¹⁴⁾.

Most studies outline the association between the polymorphism rs1801282 (Pro12Ala) and BMI. Carriers of the C allele have been shown to have naturally higher BMI when compared to non-carrier G or heterozygote G/C counterparts. A previous study assessed the interaction of macronutrient composition and BMI risk. They found a greater obesity risk in subjects who had a high carbohydrate intake with the C (Ala12) allele when compared to the non-risk G (Pro12Pro) allele. Further to this, individuals who had a high intake, combined with one just one C allele and one A allele of the FTO (rs9939609) gene had a further increased risk of obesity and higher BMI⁽¹⁵⁾. The present study did not replicate significant results associating the PPARG Ala and FTO A allele for weight pre intervention (where individuals were consuming higher levels of CHO, (T (31) = 0.54, p = 0.29). However individual data showed these risk allele individuals did have higher weight and BMI pre intervention; average weight 90.4kg and BMI 28.1 kg/m², compared to non-risk; average weight 89.4kg and BMI 27.6kg/m². Overall values in this study found that homozygote G variant of the rs1801282 lost the least amount of weight compared to their counterparts. The reasoning behind this may be due to macronutrient split. C allele individuals have higher weight on a high CHO diet, suggesting their split should favour lower CHO and higher fat. This enhanced obesity risk on a high CHO diet can be explained that in the C allele individuals, CHO cannot activate the PPARG protein, which worsens receptor activity and decreases metabolic health. In G allele individuals, their response to CHO is better for weight loss, however, this variant also is responsible for the increased storage of fatty acids in adipose tissue on a high unsaturated fat diet⁽¹⁶⁾. This explains why in this study, although G allele carriers still lost weight and BMI, it was one of the lowest values of all. These individuals should be cautious of over consuming on unsaturated fats and ensure a balanced diet whilst in a calorie deficit.

TCF7L2 rs7903146 –

The transcription factor 7-like 2 (TCF7L2)

Transcription factor 7-like 2 (TCF7L2) is involved in several functions within the cell. Its main involvement is in Wnt signalling pathways in various tissues within the body including fat, liver, brain and muscle cells. The Wnt signalling pathway is a strong activator of mitochondrial biogenesis which in turn leads to increased production of reactive oxygen species; inflammatory molecules which can damage cells and tissues. TCF7L2 regulates glucose metabolism in liver and pancreatic tissues and polymorphisms in this gene have clinical significance in type 2 diabetes and gestational diabetes through decreased insulin production, B-cell dysfunction and altered hepatic gluconeogenesis⁽¹⁷⁾.

The current study shows similar findings to previous data⁽¹⁸⁾. Results showed that the C variant of the genotype had greatest weight loss compared to the other variants. Individuals in this group responded better to the higher fat content of the diet after swapping out carbohydrates. This is not the case for the homozygous T or the heterozygous C/T. The C variant provided a protective mechanism by which the individuals still lost weight, despite being on a higher fat diet. However individually the T carriers did not lose a significant amount of weight pre and post intervention.

These results suggest that the TCF7L2 rs7903146 may operate via impaired glucagon-like peptide 1 secretion, which is stimulated by fats rather than carbohydrates⁽¹⁹⁾. Carriers of the risk allele (T) in this gene need a moderate carbohydrate intake in order to lose any fat mass as lipid levels are regulated in an insulin dependent manner.

Conclusion

Gene-diet interactions have paved a way for new scientific discoveries surrounding chronic disease related conditions, but also for a more personalised view of weight loss. To support a dietary intervention for weight loss, considering a person's genetic predisposition, genetic variants determining dietary intake and metabolism and their genetic variants to exercise are all valuable tools to ensure advice is individually tailored.

The outcome of this study shows a need to control sugar intake in the general athletic population. Although everyone was in a calorie deficit for the study, the specific macronutrient swaps that were made impacted on the ability to lose body weight over the intervention period. Data from this study has outlined specific macronutrient interactions with single nucleotide polymorphisms in multiple genes and ultimately suggests a need for more personalised nutrition.

Personalised diet preparation that includes DNA analysis may prove to be more beneficial to those wishing to lose weight and fight obesity than preparation without. Weight loss that is efficient, effective and most importantly sustainable is key, with genetic testing used in conjunction with standard analysis helping enable this.

References

1. Chung WK, Leibel RL. Considerations regarding the genetics of obesity. *Obesity*. 2008. **16 (Suppl 3):** S33-9. doi: 10.1038/oby.2008.514.
2. Rosmond R. Aetiology of obesity: a striving after wind? *Obes Rev*. 2004. **5:** 177–81. DOI: 10.1111/j.1467-789X.2004.00151.x
3. Bouchard C, Rankinen T. Exciting advances and new opportunities. In: Clement K, Sorensen TIA (eds). *Genomics of Obesity*. Taylor and Francis Group, LLC: New York, in press.
4. Rubin, D.A., McMurray, R.G., Harrell, J.S., Hackney, A.C., Thorpe, D.E., Hagg, A.M. 2008. The association between insulin resistance and cytokines in adolescents: the role of weight status and exercise. *Metabolism*. **57(5): 683 – 690**. doi: 10.1016/j.metabol.2008.01.005. PMID: PMC2678573
5. Tsukada S., Tanaka, Y., Maegawa, H., Kashiwagi, A., Kawamori, R, Maeda S. Intronic Polymorphisms within TFAP2B Regulate Transcriptional Activity and Affect Adipocytokine Gene Expression in

- Differentiated Adipocytes. *Molecular Endocrinology*. 2006. **20(5)**: 1104 – 1111. DOI: 10.1210/me.2005-0311
6. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosin kinase activity in TNF- α and obesity induced insulin resistance. *Science*. 1996. **271**:665–668. PMID: 8571133
7. Stocks T, Angquist L, Banasik K, Harder MN, Taylor MA, Hager J, Arner P, Oppert JM, Martinez JA, Polak J, Rousseau F, Langin D, Rössner S, Holst C, MacDonald IA, Kamatani Y, Pfeiffer AF, Kunesova M, Saris WH, Hansen T, Pedersen O, Astrup A, Sørensen TI. TFAP2B influences the effect of dietary fat on weight loss under energy restriction. *PLoS One*. 2012;7. DOI: 10.1371/journal.pone.0043212
8. Yeung, E., Qi, L., Hu, F. B., & Zhang, C. (2011). Novel abdominal adiposity genes and the risk of type 2 diabetes: findings from two prospective cohorts. *International Journal of Molecular Epidemiology and Genetics*. 2011. **2(2)**: 138–144. PMID: 21686128
9. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O’Kirwan F *et al*. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. *Proc Natl Acad Sci USA* 2004; **101**: 4531–4536. DOI: 10.1073/pnas.0308767101
10. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J *et al*. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet* 2007; **3**: e115. DOI: 10.1371/journal.pgen.0030115
11. Wardle, J., Carnell, S., Haworth, C., Farooqui, IS., O’Rahilly, S. Plomin, R. Obesity associated with genetic variation in FTO is associated with diminished satiety. *J Clin Endocrinol Metab*. 2008. **93(9)**: 3640-3. doi: 10.1210/jc.2008-0472. Epub
12. Grau, K, Hansen, T., Holst, C., Astrup, A., Sarris, W. Macronutrient-specific effect of FTO rs9939609 in response to a 10-week randomized hypo-energetic diet among obese Europeans.. *International Journal of Obesity*, Nature Publishing Group, 2009. DOI: 10.1038/ijo.2009.159
13. Huang, T.; Qi, Q.; Li, Y.; Hu, F.B.; Bray, G.A.; Sacks, F.M.; Williamson, D.A.; Qi, L. FTO genotype, dietary protein, and change in appetite: The preventing overweight using novel dietary strategies trial. *Am. J. Clin. Nutr*. **2014**. **99**, 1126–1130. DOI: 10.3945/ajcn.113.082164
14. Hasan, S., Kamel, N., Hamed, S., Eman, A., Hussein, N. Peroxisome proliferator-activated receptor- γ polymorphism (rs1801282) is associated with obesity in Egyptian patients with coronary artery disease and type 2 diabetes mellitus. *Journal of Genetic Engineering and Biotechnology*. 2017. **15**. 10.1016/j.jgeb.2017.08.002.
15. Galbete, C., Toledo, E, Matinez-Gonzalez, MA., Martinez JA., Guillen-Grima, F., Marti, A. 2013. Pro12Ala variant of the PPARG2 gene increases body mass index: An updates meta-analysis encompassing 49,092 subjects. *Obesity* (Silver Spring). 2013 Jul;21(7):1486-95. doi: 10.1002/oby.20150. Epub 2013 May 13.
16. Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, et al. Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary fat intake in relation to body mass. *Hum Mol Genet*. 2003. **12**: 2923–2929. pmid:14506127.
17. Jin T, Liu. "The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus". *Molecular Endocrinology*. 2008. **22** (11): 2383–92. doi:10.1210/me.2008-0135. PMID 18599616.
18. Cropano, C., Santoro, N., Groop, L., Dalla-Man, C., Cobelli, C., Galderisi, Al., Kursawe, K. 2017. The rs7903146 Variant in the TCF7L2 Gene Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing β -Cell Function and Hepatic Insulin Sensitivity. *Diabetes Care*. 2017. **40(8)**: 1082-1089. doi: 10.2337/dc17-0290. PMCID: PMC5521977
19. Engelbrechsten, L., Hansen TH., Mahendran, Y., Pyl, P. Andersson E., Jonsson, A., Gjesing A., Linneberg, A., Jorgensen T., Hansen, T., Vestergaard, H. 2017. Homozygous carriers of the TCF7L2

rs7903146 T-allele show altered postprandial response in triglycerides and triglyceride-rich lipoproteins. *Sci Rep.* 2017. **21;7**: 43128. doi: 10.1038/srep43128.

Appendix

Overall Averages from all data – minus outliers

	WeightPre	WeightPost	Height	kCAL	BMI Pre	BMI Post	Weight Loss over 24 WK	BMI Change over 24 WK
Averages	91	81	179	2548	28.1	25.2	-9	-2.9

t-Test: Paired Two Sample for Means between weight pre and postintervention

	Variable 1	Variable 2
Mean	90.55263158	81.21052632
Variance	22.41607397	30.49502134
Observations	38	38
Pearson Correlation	0.673551912	
Hypothesized Mean Difference	0	
df	37	
t Stat	13.69	
P(T<=t) one-tail	0.00	
t Critical one-tail	1.69	
P(T<=t) two-tail	0.00	
t Critical two-tail	2.03	

t-Test: Paired Two Sample for Means for BMI pre and post intervention

	<i>Variable 1</i>	<i>Variable 2</i>
Mean	28.14807544	25.24325077
Variance	2.956082802	3.544872318
Observations	38	38
Pearson Correlation	0.732555139	
Hypothesized Mean Difference	0	
df	37	
t Stat	13.50	
P(T<=t) one-tail	0.00	
t Critical one-tail	1.69	
P(T<=t) two-tail	0.00	
t Critical two-tail	2.03	

Data from 4 genes which found associations for

	TCF7L2			TFAP2B			PPARG2			FTO		
	rs7903146			rs987237 genotype			rs1801282 genotype			rs9939609 genotype		
	C	T	CT	A	G	GA	C	G	GC	T	A	TA
N	24	9	5	21	1	16	31	1	6	12	4	22
Weight Pre (kg)	90	86	89	90	89	91	90	90	90	89	91	90
Weight Post (kg)	81	83	83	82	78	81	82	84	80	79	83	83
Height (cm)	179	179	179	170	177	179	179	182	180	180	179	180
KCAL	2558	2459	2494	2566	2450	2532	2553	2450	2550	2500	2543	2573
BMI Pre	27.96	26.39	27.85	27.76	28.41	28.19	28.01	27.17	27.8	27.55	28.57	28
BMI post	25.31	25.64	25.88	25.49	24.9	25.32	25.6	25.36	24.57	24.5	25.91	25.71
Weight Loss (kg)	-8	-2	-6	-7	-11	-9	-8	-6	-10	-10	-9	-7
BMI loss	-2.6	-0.75	-1.9	-2.27	-3.51	-2.87	-2.41	-1.81	-3.23	-3.04	-2.65	-2.3